Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2026-01-04 @ 6:24 PM
Study NCT ID:
NCT06422858
Status:
RECRUITING
Last Update Posted:
2025-05-09
First Post:
2024-05-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Sponsor:
Zhejiang Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-20
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-09
First Submit QC Date:
None
Study First Post Date:
2024-05-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-05
Last Update Post Date:
2025-05-09
Last Update Post Date Type:
ACTUAL